Life science company BioDuro LLC revealed on Friday the election of Kent Payne, PhD as president of its CMC Global Solutions business.
Currently, Dr Payne is a board member for Goodwin Biotechnologies, a biological contract manufacturer, as well as board advisor for Vitruvias Therapeutics, a specialty generic pharmaceutical business.
Most recently, Dr Payne was employed as chief executive officer at Socorro Pharmaceuticals, a generic pharmaceutical company.
Previously, Dr Payne served as president Americas at Qualicaps Inc, principal consultant and partner at CoreFactor LLC and vice president/general manager at Catalent Pharma Solutions Inc. He has also held progressive leadership roles at Novartis, Monsanto and G.D. Searle.
Earlier, Dr Payne has held board and advisory roles at Life Science Institute Inc, a wholly-owned subsidiary of Mitsubishi Chemical Holdings, Technophar Inc, Qualicaps Inc and PDS Biotechnology (PDSB).
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US